Merck HPV vaccine for men approved in China
Merck & Co's human papillomavirus (HPV) vaccine, Gardasil, has received approval from China's medical products administration for men aged 9-26 years.
Gardasil, a key product for Merck alongside its blockbuster cancer treatment Keytruda, has been a significant growth driver internationally, particularly in China.
In October, Merck said weak sales in China of its Gardasil vaccine, used to prevent HPV, were likely to continue into 2025 amid weak demand among women.
Medical Dialogues team had earlier reported that Merck had received approval from the UK's Medicines and Healthcare products Regulatory Agency for its therapy, sotatercept, to treat a rare lung condition. Sotatercept gained U.S. approval in March 2024 and is sold under the brand name Winrevair. It is also approved in European Union and 30 other markets.
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.